Rapid and reliable inactivation protocols for the diagnostics of emerging viruses: The example of SARS-CoV-2 and monkeypox virus.
SARS-CoV-2
emerging pathogen
inactivation
monkeypox virus
risk management
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
06
08
2022
accepted:
22
08
2022
pubmed:
13
9
2022
medline:
11
1
2023
entrez:
12
9
2022
Statut:
ppublish
Résumé
The emergence and sustained transmission of novel pathogens are exerting an increasing demand on the diagnostics sector worldwide, as seen with the ongoing severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic and the more recent public health concern of monkeypox virus (MPXV) since May 2022. Appropriate and reliable viral inactivation measures are needed to ensure the safety of personnel handling these infectious samples. In the present study, seven commercialized diagnosis buffers, heat (56°C and 60°C), and sodium dodecyl sulfate detergent (2.0%, 1.0%, and 0.5% final concentrations) were tested against infectious SARS-CoV-2 and MPXV culture isolates on Vero cell culture. Cytopathic effects were observed up to 7 days postinoculation and viral load evolution was measured by semiquantitative polymerase chain reaction. The World Health Organization recommends an infectious titer reduction of at least 4 log
Identifiants
pubmed: 36089749
doi: 10.1002/jmv.28126
pmc: PMC9538322
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28126Informations de copyright
© 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Références
World Health Organization. Multi-country outbreak of monkeypox, external situation report #2-July 25, 2022. 2022.
Centers for Disease Control and Prevention. Monkeypox outbreak global map. 2022. Accessed July 28, 2022. https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html
Ramakrishnan MA Determination of 50% endpoint titer using a simple formula. World J Virol. 2016;5:85. doi:10.5501/wjv.v5.i2.85
Association Française de Normalisation. NF EN 14476+A2- Antiseptiques et désinfectants chimiques - Essai quantitatif de suspension pour l'évaluation de l'activité virucide dans le domaine médical - Méthode d'essai et prescriptions (Phase 2/Étape 1). AFNOR Editions; 2019. https://viewerbdc.afnor.org/html/display/T9-40j9fF341
World Health Organization. WHO guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products; 2004. https://www.who.int/publications/m/item/WHO-TRS924-Annex4
Emergency Response, WHO Headquarters (HQ). Clinical management and infection prevention and control for monkeypox: Interim rapid response guidance, 10 June 2022; 2022. https://www.who.int/publications-detail-redirect/WHO-MPX-Clinical-and-IPC-2022.1
Haut Conseil de la Santé Publique. Mesures de prévention vis-à-vis de l'infection à Monkeypox virus. Haut Conseil de la Santé Publique; 2022. https://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=1230
Jonges M, Liu WM, van der Vries E, et al. Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling. J Clin Microbiol. 2010;48:928-940. doi:10.1128/JCM.02045-09
Darnell MER, Subbarao K, Feinstone SM, Taylor DR. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J Virol Methods. 2004;121:85-91. doi:10.1016/j.jviromet.2004.06.006
Piret J, Lamontagne J, Bestman-Smith J, et al. In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses. J Clin Microbiol. 2000;38:110-119. doi:10.1128/JCM.38.1.110-119.2000
Wang TT, Lien CZ, Liu S, Selvaraj P. Effective Heat Inactivation of SARS-CoV-2. medRxiv. 2020. doi:10.1101/2020.04.29.20085498
Patterson EI, Prince T, Anderson ER, et al. Methods of inactivation of SARS-CoV-2 for downstream biological assays. J Infect Dis. 2020;222:1462-1467. doi:10.1093/infdis/jiaa507
Galasso GJ, Sharp DG. Effects of heat on the infecting, antibody-absorbing, and interfering powers of vaccinia virus. J Bacteriol. 1965;89:611-616. doi:10.1128/jb.89.3.611-616.1965
Butcher W, Ulaeto D. Contact inactivation of orthopoxviruses by household disinfectants. J Appl Microbiol. 2005;99:279-284. doi:10.1111/j.1365-2672.2005.02601.x
Batéjat C, Grassin Q, Feher M, et al. Heat inactivation of the monkeypox virus. J Biosaf Biosecurity. 2022. 4:121-123 doi:10.1101/2022.08.10.502482
Delpuech O, Douthwaite JA, Hill T, et al. Heat inactivation of clinical COVID-19 samples on an industrial scale for low risk and efficient high-throughput qRT-PCR diagnostic testing. Sci Rep. 2022;12:2883. doi:10.1038/s41598-022-06888-z
Petrillo F, Chianese A, De Bernardo M, et al. Inhibitory effect of ophthalmic solutions against SARS-CoV-2: a preventive action to block the viral transmission. Microorganisms. 2021;9:1550. doi:10.3390/microorganisms9081550
Akhter J, Quéromès G, Pillai K, et al. The combination of bromelain and acetylcysteine (BromAc) synergistically inactivates SARS-CoV-2. Viruses. 2021;13:425. doi:10.3390/v13030425
Welch SR, Davies KA, Buczkowski H, et al. Analysis of inactivation of SARS-CoV-2 by specimen transport media, nucleic acid extraction reagents, detergents, and fixatives. J Clin Microbiol. 2020;58:e01713-e01720. doi:10.1128/JCM.01713-20
Pastorino B, Touret F, Gilles M, de Lamballerie X, Charrel RN. Heat inactivation of different types of SARS-CoV-2 samples: what protocols for biosafety, molecular detection and serological diagnostics. Viruses. 2020;12:735. doi:10.3390/v12070735